Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation des nouvelles formes d'onde délivrées à l'aide du système FARAPULSE™ PFA (IMPULSE-EVO)

21 octobre 2026 mis à jour par: Boston Scientific Corporation

Évaluation multicentrique de nouvelles formes d'onde délivrées à l'aide du système FARAPULSE™ PFA chez des patients atteints de fibrillation auriculaire

This is a multicenter, prospective, single-arm, feasibility study to evaluate the safety and effectiveness of the waveforms being delivered using the FARAPULSE PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).

Aperçu de l'étude

Description détaillée

The objective of this feasibility study is to:

  • Evaluate the initial safety and acute performance of investigational waveform(s) delivered using the FARAPULSE™ PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).
  • Assess the feasibility of the ablation workflow and waveform delivery.
  • Characterize acute and chronic lesion durability, procedure efficiency, and waveform exposure patterns.

Type d'étude

Interventionnel

Inscription (Estimé)

200

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Split, Croatie, 21 000
        • Recrutement
        • Klinicki Bolnicki Centar Split
        • Chercheur principal:
          • Ante Anic
        • Contact:
      • Hong Kong, Hong Kong
        • Recrutement
        • Queen Mary Hospital
        • Contact:
        • Chercheur principal:
          • Hung Fat Tse
      • Taipei, Taïwan, 1127
        • Pas encore de recrutement
        • Taipei Veterans General Hospital-Hospital
        • Chercheur principal:
          • Li-Wei Lo
      • Prague, Tchéquie, 15030
        • Recrutement
        • Na Homolce Hospital
        • Chercheur principal:
          • Petr Neuzil
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. ≥ 18 years of age, or older if required by local law

  2. Persistent Atrial Fibrillation or Paroxysmal Atrial Fibrillation

    1. Persistent AF Documented:

      • Physician's note confirming the presence of persistent atrial fibrillation and the arrhythmia symptoms
      • Within 180 days prior to Enrollment: A 24-hour continuous ECG recording confirming continuous AF OR Two (2) ECGs from any regulatory-cleared rhythm monitoring device showing continuous AF taken at least 7 days apart.

      OR

    2. Paroxysmal AF Documented:

      • Physician's note confirming the presence of paroxysmal atrial fibrillation and the arrhythmia symptoms
      • Within 180 days of the Enrollment Date, one (1) ECG from any regulatory-cleared rhythm monitoring device showing atrial Fibrillation (AF)
  3. Willing and capable of providing informed consent

  4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center

Exclusion Criteria:

  1. Atrial exclusions - any of the following atrial conditions:

    1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if LA diameter is not available, LA non-indexed volume > 100 mL. If both values are available, only the LA diameter will be used to confirm eligibility.
    2. Any prior atrial endocardial, epicardial, or surgical ablation procedure for arrhythmia other than ablation for right-sided SVT or cavotricuspid isthmus ablation
    3. Any prior atrial surgery
    4. Current atrial myxoma
    5. Current Left Atrial Thrombus
    6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)
  2. Cardiovascular Conditions - Any of the following cardiovascular conditions:

    1. History of sustained ventricular tachycardia (VT) or any ventricular fibrillation (VF)

    2. Atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible/non-cardiac causes

    3. Cardiac Devices and Implants:

      • Current or anticipated pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy devices.
      • Interatrial baffle, patent foramen ovale, or atrial septal defect closure device or patch.
      • Any Left Atrial Appendage Closure or Occlusion Device, except a WATCHMAN™ device implanted > 90 days before Enrollment
    4. Valvular Disease - Presence of any of the following:

      • Any prosthetic heart valve, ring or repair
      • Moderate to severe mitral valve stenosis
      • More than moderate mitral regurgitation (≥ 3+)
      • Moderate to severe aortic stenosis
    5. Cardiomyopathy - Hypertrophic cardiomyopathy

    6. Access Issues - Any IVC filter, known inability to obtain vascular access, or other contraindication to femoral access

    7. Anticipated Cardiac Surgery - Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months

  3. Congenital Conditions - Any of the following congenital conditions:

    a. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality

  4. Baseline Conditions - Any of the following conditions at Baseline:

    1. Heart failure - Heart failure associated with NYHA Class III or IV
    2. Ejection Fraction - Most recent documented LVEF < 40% within the previous 12 months
    3. Obesity: Body Mass Index (BMI) > 45.0 kg/m^2
    4. Hematologic Condition: Known coagulopathy or bleeding disorder
    5. Anticoagulation Contraindication: Contraindication to, or unwillingness to use, systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation
    6. Pregnancy - Women who are confirmed to be pregnant or lactating at the time of the ablation procedure
    7. Pulmonary Disease - Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen
    8. Malignancy - Active malignancy (other than non-melanoma skin cancers)
    9. Gastrointestinal - Clinically significant gastrointestinal problems involving the esophagus or stomach, including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration
    10. Infection - Known active systemic infection
    11. Sleep Apnea - Untreated diagnosed obstructive sleep apnea with apnea-hypopnea index classification of severe (> 30 events per hour) as per the guidelines
    12. Life Expectancy - Predicted life expectancy of less than one (1) year per investigator medical judgment
    13. Concurrent Enrollment - Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility
  5. Any of the following events within 90 days of the Consent Date:

    1. Coronary disease - Myocardial infarction (MI), unstable angina or coronary intervention
    2. Pericardium - Pericarditis or symptomatic pericardial effusion
    3. GI Bleeding - Gastrointestinal bleeding
    4. Cardiac Surgery - Any cardiac surgery
    5. Neurovascular Event - Stroke, TIA, or intracranial bleeding
    6. Thromboembolism - Any active non-neurologic thrombus and/or thromboembolic event
    7. Carotid Intervention - Carotid stenting or endarterectomy
    8. Diabetes - Uncontrolled diabetes mellitus or a recorded HgbA1c > 8.0%
  6. Medical History - Any of the following conditions in the Medical History

    1. Transplantation - Solid organ or hematologic transplant, or currently being evaluated for a transplant
    2. Diaphragmatic Abnormality - Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis
    3. Coronary Disease - Any documented history of Prinzmetal angina or severe non-revascularizable coronary disease
    4. Renal Disease - Renal insufficiency if an estimated glomerular filtration rate (eGFR) is < 30 mL/min/1.73 m2, or with any history of renal dialysis or renal transplant
    5. General Medical Conditions - Any other general health conditions that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: FARAPULSE™ Pulsed Field Ablation (PFA) System

Single Arm Prospective

The FARAWAVE™ PFA Catheter will be used to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation.

The FARASTAR™ Generator will be used in conjunction with the FARAWAVE™ PFA Catheter to deliver the investigational waveform(s) for the isolation of pulmonary veins and posterior wall in the treatment of paroxysmal and persistent atrial fibrillation.

The FARADRIVE™ Steerable Sheath will be used for percutaneous catheter introduction into the chambers of the heart, including the left side of the heart through the interatrial septum.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Device or procedure-related Composite Adverse Events (CAEs)
Délai: Ablation Procedure Day 0 - Day 7; Day 0 - Day 30; Day 0 - Day 60

The incidence of device or procedure-related Composite Adverse Events (CAEs) following the Index Procedure will be evaluated.

Ablation Procedure Day 0 - Day 7; Day 0 - Day 30; Day 0 - Day 60
Acute Procedural Success
Délai: During the Ablation Procedure

The proportion of subjects with percutaneous endocardial creation of a complete, electrically isolating set of lesions around the ostia of the pulmonary veins (PV) and posterior wall (PW) during the Index Procedure, as clinically assessed by entrance and/or exit block or confirmed by electroanatomic mapping.

During the Ablation Procedure

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

12 février 2026

Achèvement primaire (Estimé)

1 février 2028

Achèvement de l'étude (Estimé)

1 février 2028

Dates d'inscription aux études

Première soumission

11 février 2026

Première soumission répondant aux critères de contrôle qualité

26 février 2026

Première publication (Réel)

2 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

21 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner